



Kenneth C. Anderson, MD

Director, LeBow Institute for Myeloma Therapeutics  
Director, Jerome Lipper Multiple Myeloma Center

American Cancer Society Clinical Research Professor  
Kraft Family Professor of Medicine  
Harvard Medical School

Dana-Farber Cancer Institute  
450 Brookline Avenue  
Boston, Massachusetts 02215-5450  
617.632.2144 tel  
617.632.2140 fax  
kenneth\_anderson@dfci.harvard.edu  
www.dana-farber.org

November 6, 2020

To Whom It May Concern:

I am writing to most enthusiastically support the promotion of Dr. Artur Jurczyszyn. He earned his MD and PhD degrees at Jagiellonian University College of Medicine. Thereafter he has carried out translational studies in hematologic malignancy, focusing on multiple myeloma, at University Hospital in Krakow. I have known Dr. Jurczyszyn personally and professionally for 15 years.

Dr. Jurczyszyn has been instrumental in establishing a cooperative myeloma network in Poland for clinical trials and correlative studies and increasing awareness, research, education, and standard of treatment of myeloma nationally. As a testament to his expertise, he has been principal investigator on clinical trials of multiple novel targeted agents in myeloma including velcade, thalidomide and lenalidomide, and carfilzomib, as well as monoclonal antibodies elotuzumab and daratumumab. These agents already have transformed the treatment paradigm in myeloma and will continue to improve the lives of myeloma patients in Poland and around the world. Moreover, he has established a Poland Myeloma Foundation to support access of patients to these state-of-the-art treatments. As a testament of his internationally recognized expertise in myeloma, he is an active member of the International Myeloma Working Group, and helped to establish current state of the art guidelines for diagnosis, prognosis, and treatment of myeloma and other plasma cell diseases.

He has presented his work at international forums including the European Hematology Association, American Society of Hematology, and the International Myeloma Workshop. He is an excellent teacher, mentor, and role model. I have personally attended his lectures which are comprehensive and appropriately targeted to his audience. As a further testament to his clinical research and teaching expertise he has published his studies in peer-reviewed journals including Journal of Clinical Oncology, Leukemia, Bone Marrow Transplantation, Leukemia Research, Clinical Lymphoma, Myeloma and Leukemia, and Hematologic Oncology. Finally, he has also written authoritative reviews, further attesting to his teaching and clinical expertise in this area.

In summary, Dr. Jurczyszyn has established a myeloma center of excellence in Krakow and a myeloma clinical trial network in Poland, which has directly improved the practice of medicine

in myeloma nationally. He is both nationally and internationally recognized for his expertise and an acclaimed leader in his field who has made seminal contributions leading to improved treatments and patient outcome. I therefore recommend his promotion with the highest degree of enthusiasm and without reservation.

Sincerely,

Kenneth C. Anderson, MD